Medical innovations typically take 17 years from the time a lightbulb goes off in a scientist's head until the first person benefits. But every once in a while, an idea is so powerful and so profound ...
The progress of EDIT-301 in Phase 1/2 RUBY and EdiTHAL studies is encouraging. I am increasingly turning more bearish on EDIT due to increased competition and a less attractive financial outlook. The ...
Sizable investments. High-profile appearances at industry events. Unique development platforms. These elements would augur well for companies of any kind—and companies hoping to bring epigenome ...
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, ...
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial ...
‘These data open a new era of medicine – one that holds the potential of curing genetic disease,’ Intellia said. Its shares are higher. Intellia Therapeutics (NTLA) shares soared after the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results